Outlook: the profit problem in antibiotic R&D.
Economists, a biomedical researcher and a business executive have formulated three contrasting proposals to address the shortfall in antibiotic R&D. Their proposals, which emphasize advance purchase contracts, not-for-profit research, and tax incentives, respectively, share some features with provisions in bills pending before the US Congress that could potentially reshape the R&D landscape for this essential class of drugs.
Nathan
Carl
C
Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA. cnathan@med.cornell.edu
Goldberg
Frederick M
FM
D000900:Anti-Bacterial Agents / Q000191:economics*; D035843:Biomedical Research / Q000191:economics* / Q000331:legislation & jurisprudence; D015195:Drug Design; D004345:Drug Industry / Q000191:economics*; D006077:Government Agencies; D040541:Marketing / Q000191:economics*; D012109:Research Support as Topic / Q000191:economics* / Q000331:legislation & jurisprudence; D014481:United States
D000900:Anti-Bacterial Agents